​

IDEAYA Biosciences (IDYA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IDYA Stock Forecast

IDEAYA Biosciences stock forecast is as follows: an average price target of $53.33 (represents a 108.24% upside from IDYA’s last price of $25.61) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

IDYA Price Target

The average price target for IDEAYA Biosciences (IDYA) is $53.33 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $66.00 to $27.00. This represents a potential 108.24% upside from IDYA's last price of $25.61.

IDYA Analyst Ratings

Buy

According to 14 Wall Street analysts, IDEAYA Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for IDYA stock is 0 'Strong Buy' (0.00%), 12 'Buy' (85.71%), 2 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

IDEAYA Biosciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Andrew BerensLeerink Partners$27.00$29.58-8.72%5.43%
Oct 24, 2024David DaiUBS$50.00$29.5069.49%95.24%
Sep 25, 2024Graig SuvannavejhMizuho Securities$55.00$31.3775.33%114.76%
Sep 23, 2024Corinne JenkinsGoldman Sachs$48.00$33.7342.31%87.43%
Sep 23, 2024Ben BurnettStifel Nicolaus$66.00$33.7395.67%157.71%
Sep 23, 2024Justin ZelinBTIG$62.00$33.8783.05%142.09%
Sep 10, 2024Ben BurnettStifel Nicolaus$68.00$36.9783.93%165.52%
Aug 27, 2024Yigal NochomovitzCitigroup$58.00$39.8045.73%126.47%
Aug 07, 2024Matthew BieglerOppenheimer$53.00$35.8647.80%106.95%
Jul 10, 2024Gregory RenzaRBC Capital$61.00$37.3363.41%138.19%
Jul 08, 2024Graig SuvannavejhMizuho Securities$50.00$40.2024.38%95.24%
Jun 03, 2024Ben BurnettStifel Nicolaus$63.00$38.8962.00%146.00%
Dec 28, 2022Capital One Financial$29.00$17.4766.00%13.24%
Sep 13, 2022Guggenheim$32.00$12.40158.06%24.95%
Aug 18, 2022Oppenheimer$20.00$9.83103.46%-21.91%
Aug 16, 2022Robert W. Baird$18.00$10.7467.60%-29.71%

The latest IDEAYA Biosciences stock forecast, released on Nov 05, 2024 by Andrew Berens from Leerink Partners, set a price target of $27.00, which represents a -8.72% decrease from the stock price at the time of the forecast ($29.58), and a 5.43% increase from IDYA last price ($25.61).

IDEAYA Biosciences Price Target by Period

1M3M12M
# Anlaysts-612
Avg Price Target-$51.33$55.08
Last Closing Price$25.61$25.61$25.61
Upside/Downside-100.00%100.43%115.07%

In the current month, the average price target of IDEAYA Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to IDEAYA Biosciences's last price of $25.61. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024Leerink PartnersMarket PerformDowngrade
Oct 24, 2024UBSBuyInitialise
Oct 15, 2024Cantor FitzgeraldOverweightInitialise
Sep 24, 2024RBC CapitalOutperformOutperformHold
Sep 23, 2024CitigroupBuyBuyHold
Sep 23, 2024Goldman SachsBuyBuyHold
Sep 23, 2024BTIGBuyBuyHold
Sep 23, 2024OppenheimerOutperformOutperformHold
Aug 27, 2024CitigroupBuyBuyHold
Aug 07, 2024OppenheimerOutperformOutperformHold
Jul 10, 2024RBC CapitalOutperformOutperformHold
Jul 08, 2024BTIGBuyBuyHold
Jul 08, 2024OppenheimerOutperformOutperformHold
Feb 21, 2024RBC CapitalBuyBuyHold
Jan 25, 2024Goldman SachsBuyBuyHold
Jan 10, 2024WedbushBuyBuyHold
Sep 12, 2023Goldman SachsBuyBuyHold
Dec 28, 2022Janney MontgomeryBuyInitialise
Dec 28, 2022Morgan StanleyEqual-WeightInitialise
Oct 27, 2022NeedhamBuyInitialise
Oct 27, 2022Raymond JamesOutperformInitialise
Oct 27, 2022CitigroupBuyInitialise
Sep 13, 2022GuggenheimBuyBuyHold
Aug 18, 2022OppenheimerOutperformOutperformHold

IDEAYA Biosciences's last stock rating was published by Leerink Partners on Nov 05, 2024. The company Downgrade its IDYA rating from "null" to "Market Perform".

IDEAYA Biosciences Financial Forecast

IDEAYA Biosciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
Revenue-------------$8.04M$3.54M$7.88M$4.02M$29.70M$5.85M$11.36M$-38.02M$24.98M$8.76M$7.25M$10.57M$8.97M-
Avg Forecast$13.02M$9.39M$7.40M$3.96M$3.45M$1.27M$1.27M$1.27M$5.36M$4.27M$4.46M$5.43M$8.84M$8.38M$4.89M$6.14M$7.00M$6.64M$7.69M$6.71M$8.98M$8.55M$14.24M$7.48M$7.92M$70.56M$100.00M
High Forecast$16.31M$11.76M$9.27M$4.97M$4.32M$1.59M$1.59M$1.59M$6.72M$4.31M$4.46M$5.43M$17.39M$10.50M$6.13M$7.70M$8.77M$6.64M$7.69M$6.71M$8.98M$8.55M$14.24M$7.48M$7.92M$70.56M$100.00M
Low Forecast$9.71M$7.00M$5.52M$2.96M$2.57M$944.71K$944.71K$944.71K$4.00M$4.24M$4.46M$5.43M$3.48M$6.25M$3.65M$4.58M$5.22M$6.64M$7.69M$6.71M$8.98M$8.55M$14.24M$7.48M$7.92M$70.56M$100.00M
# Analysts2222111484336109988889999999
Surprise %-------------0.96%0.72%1.28%0.57%4.47%0.76%1.69%-4.23%2.92%0.61%0.97%1.33%0.13%-

IDEAYA Biosciences's average Quarter revenue forecast for Dec 23 based on 6 analysts is $8.84M, with a low forecast of $3.48M, and a high forecast of $17.39M. IDYA's average Quarter revenue forecast represents a 10.03% increase compared to the company's last Quarter revenue of $8.04M (Sep 23).

IDEAYA Biosciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts2222111484336109988889999999
EBITDA-------------$-33.53M$-32.71M$-26.28M$-26.44M$1.58M$-21.30M$-11.66M$1.76M$-29.92M$-10.50M$-8.64M$355.87K$-4.58M$-12.05M
Avg Forecast$-7.81M$-5.63M$-4.44M$-2.38M$-2.07M$-760.00K$-760.00K$-760.00K$-3.22M$-2.56M$-2.67M$-3.26M$-5.31M$-5.03M$-2.93M$-3.69M$-4.20M$-3.99M$-4.62M$-17.32M$-5.39M$-5.13M$-8.55M$-8.32M$-4.75M$-42.33M$-60.00M
High Forecast$-5.83M$-4.20M$-3.31M$-1.77M$-1.54M$-566.83K$-566.83K$-566.83K$-2.40M$-2.55M$-2.67M$-3.26M$-2.09M$-3.75M$-2.19M$-2.75M$-3.13M$-3.99M$-4.62M$-13.85M$-5.39M$-5.13M$-8.55M$-6.66M$-4.75M$-42.33M$-60.00M
Low Forecast$-9.79M$-7.06M$-5.56M$-2.98M$-2.59M$-952.27K$-952.27K$-952.27K$-4.03M$-2.58M$-2.67M$-3.26M$-10.44M$-6.30M$-3.68M$-4.62M$-5.26M$-3.99M$-4.62M$-20.78M$-5.39M$-5.13M$-8.55M$-9.98M$-4.75M$-42.33M$-60.00M
Surprise %-------------6.67%11.14%7.13%6.30%-0.40%4.61%0.67%-0.33%5.83%1.23%1.04%-0.07%0.11%0.20%

8 analysts predict IDYA's average Quarter EBITDA for Dec 22 to be $-4.20M, with a high of $-3.13M and a low of $-5.26M. This is -364.98% lower than IDEAYA Biosciences's previous annual EBITDA (Sep 22) of $1.58M.

IDEAYA Biosciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts2222111484336109988889999999
Net Income-------------$-27.44M$-27.93M$-20.04M$-21.96M$2.57M$-21.61M$-17.99M$21.88M$-31.55M$-10.95M$-9.02M$-5.13K$-4.93M$-12.39M
Avg Forecast$-74.36M$-74.10M$-72.61M$-72.12M$-64.00M$-62.61M$-58.97M$-55.94M$-54.19M$-55.82M$-46.16M$-44.40M$-40.31M$-42.16M$-47.56M$-46.66M$-47.83M$-47.26M$-39.38M$-18.07M$-24.26M$-23.59M$-5.46M$-8.69M$-23.34M$228.24M$142.45M
High Forecast$-49.79M$-49.62M$-48.61M$-48.29M$-42.85M$-41.92M$-39.49M$-51.40M$-50.15M$-37.38M$-30.91M$-29.73M$-27.97M$-21.51M$-31.84M$-31.24M$-32.03M$-47.26M$-39.38M$-14.46M$-24.26M$-23.59M$-5.46M$-6.95M$-23.34M$228.24M$142.45M
Low Forecast$-98.82M$-98.48M$-96.48M$-95.84M$-85.04M$-83.20M$-78.37M$-63.49M$-58.24M$-74.18M$-61.35M$-59.00M$-54.29M$-66.25M$-63.20M$-62.01M$-63.56M$-47.26M$-39.38M$-21.68M$-24.26M$-23.59M$-5.46M$-10.42M$-23.34M$228.24M$142.45M
Surprise %-------------0.65%0.59%0.43%0.46%-0.05%0.55%1.00%-0.90%1.34%2.01%1.04%0.00%-0.02%-0.09%

IDEAYA Biosciences's average Quarter net income forecast for Dec 22 is $-47.83M, with a range of $-63.56M to $-32.03M. IDYA's average Quarter net income forecast represents a -1961.20% decrease compared to the company's last Quarter net income of $2.57M (Sep 22).

IDEAYA Biosciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts2222111484336109988889999999
SG&A-------------$7.86M$7.08M$6.30M$5.75M$6.67M$5.55M$5.92M-$14.83M$4.83M$4.82M$3.80M$3.94M$3.99M
Avg Forecast$10.87M$7.84M$6.18M$3.31M$2.88M$1.06M$1.06M$1.06M$4.48M$3.57M$3.72M$4.54M$7.38M$7.00M$4.08M$5.13M$5.84M$5.55M$6.42M$6.65M$7.50M$7.14M$11.89M$4.64M$6.62M$58.91M$83.49M
High Forecast$13.62M$9.82M$7.74M$4.15M$3.61M$1.33M$1.33M$1.33M$5.61M$3.59M$3.72M$4.54M$14.52M$8.77M$5.12M$6.43M$7.32M$5.55M$6.42M$7.97M$7.50M$7.14M$11.89M$5.57M$6.62M$58.91M$83.49M
Low Forecast$8.11M$5.84M$4.61M$2.47M$2.15M$788.72K$788.72K$788.72K$3.34M$3.54M$3.72M$4.54M$2.90M$5.22M$3.05M$3.82M$4.36M$5.55M$6.42M$5.32M$7.50M$7.14M$11.89M$3.71M$6.62M$58.91M$83.49M
Surprise %-------------1.12%1.73%1.23%0.98%1.20%0.86%0.89%-2.08%0.41%1.04%0.57%0.07%0.05%

IDEAYA Biosciences's average Quarter SG&A projection for Dec 23 is $7.38M, based on 6 Wall Street analysts, with a range of $2.90M to $14.52M. The forecast indicates a -6.09% fall compared to IDYA last annual SG&A of $7.86M (Sep 23).

IDEAYA Biosciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts2222111484336109988889999999
EPS-------------$-0.46$-0.00$-0.41$-0.46$0.06$-0.56$-0.47$0.57$-0.31$-0.33$-0.28$-0.00$-0.17$-0.59
Avg Forecast$-0.86$-0.86$-0.84$-0.84$-0.74$-0.73$-0.68$-0.65$-0.63$-0.65$-0.54$-0.52$-0.47$-0.49$-0.55$-0.54$-0.55$-0.61$-0.51$-0.41$-0.31$-0.30$-0.07$-0.30$-0.30$2.93$1.83
High Forecast$-0.58$-0.58$-0.56$-0.56$-0.50$-0.49$-0.46$-0.60$-0.58$-0.43$-0.36$-0.34$-0.32$-0.25$-0.37$-0.36$-0.37$-0.61$-0.51$-0.41$-0.31$-0.30$-0.07$-0.30$-0.30$2.93$1.83
Low Forecast$-1.15$-1.14$-1.12$-1.11$-0.99$-0.97$-0.91$-0.74$-0.68$-0.86$-0.71$-0.68$-0.63$-0.77$-0.73$-0.72$-0.74$-0.61$-0.51$-0.41$-0.31$-0.30$-0.07$-0.30$-0.30$2.93$1.83
Surprise %-------------0.94%0.00%0.76%0.83%-0.11%1.11%1.14%-1.83%1.02%4.71%0.94%0.00%-0.06%-0.32%

According to 8 Wall Street analysts, IDEAYA Biosciences's projected average Quarter EPS for Dec 22 is $-0.55, with a low estimate of $-0.74 and a high estimate of $-0.37. This represents a -969.87% decrease compared to IDYA previous annual EPS of $0.06 (Sep 22).

IDEAYA Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$2.37$33.861328.69%Buy
KROSKeros Therapeutics$18.00$102.00466.67%Buy
INZYInozyme Pharma$2.94$16.00444.22%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
ANABAnaptysBio$15.99$49.83211.63%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
SNDXSyndax Pharmaceuticals$13.63$31.67132.36%Buy
IDYAIDEAYA Biosciences$26.33$53.33102.54%Buy
SWTXSpringWorks Therapeutics$37.72$76.00101.48%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
RNAAvidity Biosciences$32.74$59.0080.21%Buy
MLTXMoonLake Immunotherapeutics$56.30$100.0077.62%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
PTGXProtagonist Therapeutics$40.69$57.3340.89%Buy
MGTXMeiraGTx$6.40$9.0040.63%Buy
VRNAVerona Pharma$41.66$39.50-5.18%Buy

IDYA Forecast FAQ

Is IDEAYA Biosciences a good buy?

Yes, according to 14 Wall Street analysts, IDEAYA Biosciences (IDYA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 85.71% of IDYA's total ratings.

What is IDYA's price target?

IDEAYA Biosciences (IDYA) average price target is $53.33 with a range of $27 to $66, implying a 108.24% from its last price of $25.61. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will IDEAYA Biosciences stock go up soon?

According to Wall Street analysts' prediction for IDYA stock, the company can go up by 108.24% (from the last price of $25.61 to the average price target of $53.33), up by 157.71% based on the highest stock price target, and up by 5.43% based on the lowest stock price target.

Can IDEAYA Biosciences stock reach $40?

IDYA's average twelve months analyst stock price target of $53.33 supports the claim that IDEAYA Biosciences can reach $40 in the near future.

What are IDEAYA Biosciences's analysts' financial forecasts?

IDEAYA Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $7.25M (high $9.08M, low $5.41M), average EBITDA is $-4.35M (high $-3.244M, low $-5.45M), average net income is $-242M (high $-176M, low $-310M), average SG&A $6.05M (high $7.58M, low $4.51M), and average EPS is $-2.802 (high $-2.038, low $-3.598). IDYA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $33.77M (high $42.31M, low $25.18M), average EBITDA is $-20.26M (high $-15.11M, low $-25.386M), average net income is $-293M (high $-196M, low $-390M), average SG&A $28.19M (high $35.32M, low $21.03M), and average EPS is $-3.402 (high $-2.278, low $-4.521).

Did the IDYA's actual financial results beat the analysts' financial forecasts?

Based on IDEAYA Biosciences's last annual report (Dec 2022), the company's revenue was $50.93M, beating the average analysts forecast of $28.04M by 81.61%. Apple's EBITDA was $-62.502M, beating the average prediction of $-30.117M by 107.53%. The company's net income was $-54.808M, missing the average estimation of $-153M by -64.07%. Apple's SG&A was $23.9M, missing the average forecast of $24.46M by -2.29%. Lastly, the company's EPS was $-1.32, missing the average prediction of $-2.077 by -36.46%. In terms of the last quarterly report (Sep 2023), IDEAYA Biosciences's revenue was $8.04M, missing the average analysts' forecast of $8.38M by -4.08%. The company's EBITDA was $-33.526M, beating the average prediction of $-5.028M by 566.82%. IDEAYA Biosciences's net income was $-27.44M, missing the average estimation of $-42.158M by -34.91%. The company's SG&A was $7.86M, beating the average forecast of $7M by 12.39%. Lastly, the company's EPS was $-0.46, missing the average prediction of $-0.489 by -5.96%